WHO ICTRP trial
Phase II study for Anti-PD1 therapy combined with GEMOX for relapse/refractory…
ChiCTR1900022826 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR1900022826 |
|---|---|
| Public title | Phase II study for Anti-PD1 therapy combined with GEMOX for relapse/refractory Nasal Natural Killer/T-Cell Lymphoma failure to Peg-ASP-based regimen: a prospective single-center clinical trial |
| Scientific title | Phase II study for Anti-PD1 therapy combined with GEMOX for relapse/refractory Nasal Natural Killer/T-Cell Lymphoma failure to Peg-ASP-based regimen: a prospective single-center clinical trial |
| Primary sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | 2 |
| Countries | China |
| Conditions | NK/T cell lymphoma |
| Interventions | 1:Anti-PD1+GEMOX |
| Registration date | Apr 27, 2019 |
| Target size | 1:80 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: